Liminatus Pharma, Inc.
LIMN
$0.14
$0.013.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -11.33M | -10.53M | -2.59M | -1.37M | -3.87M |
| Total Depreciation and Amortization | 2.20K | 1.70K | 1.20K | 700.00 | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.23M | 7.23M | -166.30K | -1.27M | -- |
| Change in Net Operating Assets | -7.88M | -6.82M | -7.12M | -6.84M | 2.26M |
| Cash from Operations | -11.98M | -10.12M | -9.88M | -9.48M | -1.61M |
| Capital Expenditure | -13.10K | -13.10K | -13.10K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -775.00K | -1.35M | -1.90M | -2.70M | -3.43M |
| Cash from Investing | -788.10K | -1.36M | -1.91M | -2.70M | -3.43M |
| Total Debt Issued | 4.34M | 5.05M | 5.75M | 6.74M | 4.64M |
| Total Debt Repaid | -1.30M | -1.30M | -1.30M | -1.30M | -- |
| Issuance of Common Stock | 14.14M | 10.56M | 10.56M | 10.56M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.56M | -2.56M | -2.56M | -2.53M | 0.00 |
| Cash from Financing | 14.62M | 11.75M | 12.45M | 13.46M | 4.64M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.85M | 260.00K | 656.10K | 1.28M | -399.50K |